^
    11ms
    #ASCO23 Abs9025 #LCSM 🔬 SI-B001 + chemotherapy for locally advanced or metastatic EGFR/ALK wild-type NSCLC: Phase II study results 📋. ➡️ 55 patients enrolled, 48 evaluable for efficacy 💉. ➡️ ORR of 31.3% (15/48), DCR of 77.1% (37/48) 👏. ➡️ In Cohort B, Schedule 1, ORR was… https://t.co/DTfV3HzPHu (@ADesaiMD)
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • ALK wild-type
    |
    izalontamab (SI-B001)
    1year
    Includes resectable stage II/III (AJCC v8), EGFR/ALK wild type NSCLC. Pts receive 3 cycles of neoadjuvant chemotherapy + toripalimab vs placebo then surgery then 1 more cycle of adjuvant chemo (+tori/pbo) then 13 doses of maintenance toripalimab vs placebo. #ASCOPlenarySeries (@StephenVLiu)
    Clinical • Surgery
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • ALK wild-type
    |
    Loqtorzi (toripalimab-tpzi)
    over1year
    Patients with PDL1 high NSCLC (EGFR/ALK wild type) randomized to zimberelimab (PD-1) alone, zim + domvanalimab (TIGIT), or zim + dom + etrumadenant (A2R). Co-primary endpoints of RR and PFS. About 50 pts per arm. (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    EGFR wild-type • ALK wild-type
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    over1year
    First-Line Tremelimumab/Durvalumab/Chemotherapy May Become New Standard of Care in EGFR/ALK Wild-Type NSCLC #lungcancer #lcsm #oncology #nursing @MLJohnsonMD2 https://t.co/txav98AF82 (@OncNursingNews)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab)
    over1year
    For PD-L1 positive and EGFR/ALK wild type NSCLC, it is highly possible that neoadjuvant IO is better than adjuvant IO. (@JoeChangMD)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK positive • EGFR wild-type • ALK wild-type • EGFR positive
    over2years
    I agree and wouldn't use the release to guide therapy. I think the topline reinforces the IMpower 010 results. I would stick to the published data and the approved agent in this setting: atezolizumab for PDL1+ (especially PDL1 high), EGFR/ALK wild type, stage II/III NSCLC. (@StephenVLiu)
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Tecentriq (atezolizumab)